A medicine company dedicated to providing comprehensive and integrated services in terms of registration, import, logistics and brand promotion of original drugs.
Based in China and facing the international market
Zhejiang Hesenna Medicine Co., Ltd., the main body of the Group (hereinafter referred to as HSN), was established in Lishui City, Zhejiang Province in 2020. Based in China and facing the world, HSN is committed to building a pharmaceutical group that provides integrated services of commercialization, supply chain and brand promotion of foreign original drugs in China. Hesenna (Guangdong) Healthcare Consulting & Servicing Co., Ltd, a wholly-owned subsidiary of HSN, focuses on building professional, compliant and efficient commercial operation, which has established a professional brand image for many high-quality products.
HSN’s professionalism and integrated services in the pharmaceutical field have been highly recognized and trusted by many leading pharmaceutical companies, such as Pharmanovia (UK), Roche (Switzerland), CHEPLAPHARM (Germany), Bioprojet (France), Patheon (France), Inpharmasci (France), etc. HSN has established deep strategic partnerships with several pharmaceutical companies in the early stage of the product life cycle, and obtained authorization during the product development and application stage to become the MAH or its local agent in China, leading its filing in China and the professional layout of product branding. HSN currently focuses on two major areas: bone health and women’s health, covering more than 110,000 medical institutions and about 80,000 pharmacies in China.
In the field of bone health, HSN promotes the implementation of the osteoporosis integrated diagnosis and treatment scheme, including promoting the registration and marketing of Bonviva® (Film-coated Tablets Ibandronic Acid) in China (currently approved for use in Hainan Boao Lecheng International Medical Tourism Pilot Zone). In April 2023, Pharmanovia & HSN kicked off “Leaping Tiger” project and HSN became the CSO of Rocaltrol® (Calcitriol Soft Capsules) in China, responsible for the national marketing and promotion of the product. At the same time, HSN promotes the integrated solutions of osteoporosis diagnosis and treatment by introducing LINGLONG® AI DXA Machine (dual energy X-ray absorptiometry).
In the field of mental health, HSN has already made inroads into the rare disease domain. Since 2023, it has formed a strategic partnership with RareStone Group to jointly promote the commercialization of Wakix® (Pitolisant Hydrochloride Tablets) with Citrine Medicine. HSN will focus on promoting the development of diagnosis and treatment for narcolepsy, providing effective medication for and benefiting more narcolepsy patients.
HSN focuses on bone health, oncology, mental health and women’s health. At present, the research and development products cover osteoporosis, oncology, narcolepsy and gynecological diseases. In the future, HSN will continue to expand the field of disease in China.
Innovate ｜ Win-Win｜Cooperation｜Development
Based in China and facing the world, HSN is a pharmaceutical group that provides integrated services of Commercialization, supply chain, and brand promotion of foreign high-end patented drugs in China. An emerging strategic partner for your brand.
Copyright © 2024 – Hesenna Medicine All rights reserved.
